Patients with diabetic macular oedema (DME) who received aflibercept injection demonstrated a significantly greater improvement in mean change in best-corrected visual acuity (BCVA) from baseline at 52 weeks compared to those who received either bevacizumab or ranibizumab.
Patients with diabetic macular oedema (DME) who received aflibercept injection (EYLEA, Bayer HealthCare) demonstrated a significantly greater improvement in mean change in best-corrected visual acuity (BCVA) from baseline at 52 weeks compared to those who received either bevacizumab or ranibizumab.
That was the top-line result shared with study investigators in the Diabetic Retinopathy Clinical Research Network (DRCR.net) comparative effectiveness study. DRCR.net is in the process of finalizing and verifying the data prior to submission for publication.
Other findings:
The independent, US National Institutes of Health-sponsored Diabetic Retinopathy Clinical Research Network study was designed to compare three anti-VEGF therapies for the treatment of DME. It enrolled 660 patients who were randomized to receive either aflibercept 2 mg, bevacizumab 1.25 mg, or ranibizumab 0.3 mg dosed according to a protocol-specified algorithm. Mean change in BCVA from baseline at 52 weeks was the study's primary endpoint.
Full details of the protocol can be found at www.drcr.net